Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iproniazid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.90 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.90 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iproniazid SCHEMBL4153 | 0.95 | MAOA (1.00) | HPGDLMNAMAOAMAOBPTGS2 | |
| Iproniazid SCHEMBL3597361 | 0.93 | MAOA (0.96) | HPGDLMNAMAOAMAOBPTGS2 | |
| Iproniazid SCHEMBL3001881 | 0.93 | MAOA (0.96) | HPGDLMNAMAOAMAOBPTGS2 | |
| Iproniazid SCHEMBL15200763 | 0.88 | HPGD (1.00) | HPGDLMNAMAOAMAOBPTGS2 | |
| SCHEMBL3001440 | 0.78 | MAOA (0.70) | HPGDLMNAMAOAMAOBPTGS2 | |
| SCHEMBL3363035 | 0.78 | MAOA (0.70) | HPGDLMNAMAOAMAOBPTGS2 | |
| Iproclozide SCHEMBL28086223 | 0.77 | MAOA (0.62) | HPGDLMNAMAOAMAOBPTGS2 | |
| SCHEMBL2999066 | 0.77 | MAOA (0.68) | HPGDLMNAMAOAMAOBPTGS2 | |
| SCHEMBL2992964 | 0.77 | ALDH1A1 (1.00) | HPGDLMNAMAOAMAOBPTGS2 | |
| SCHEMBL2989617 | 0.76 | MAOA (0.67) | HPGDLMNAMAOAMAOBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025133679-A1 | COMPOUNDS AND COMPOSITION FOR DNA PROTECTION | ASSOCIAÇÃO PARA DESENVOLVIMENTO DO CENTRO ACADÉMICO DE INVESTIGAÇÃO E FORMAÇÃO BIOMÉDICA DO ALGARVE, AD-ABC (PT) | 2025-06-26 | — | — | WO | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| WO-2023059810-A1 | STENTS AND METHODS OF USE | UNIVERSITY OF CONNECTICUT (US) | 2023-04-13 | — | — | WO | claimed |
| WO-2023044463-A1 | SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS | UNIVERSITY OF CONNECTICUT (US) | 2023-03-23 | — | — | WO | claimed |
| CN-108329734-A | A kind of preparation method of wear-resisting horizontal bar | 安徽兴乐健身器材有限公司 | 2018-07-27 | — | — | CN | claimed |
| CN-105805426-B | Pipeline runs through device | 上海火克新材料有限公司 | 2017-10-27 | — | — | CN | claimed |
| US-8703764-B2 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE JAMES (CA) | 2014-04-22 | — | — | US | claimed |
| EP-1713486-A4 | COMBINATION THERAPY FOR DEMENTIA,DEPRESSION AND APATHY | SHELDON LESLIE JAMES (CA) | 2009-04-29 | — | — | EP | claimed |
| EP-1094790-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATION | Cascade Development, Inc. (US) | 2001-05-02 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000001369-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATION | CASCADE DEVELOPMENT, INC. (US) | 2000-01-13 | — | — | WO | claimed |
| US-5968554-A | DRUG DELIVERY WITH CORE AND PROTECTIVE COATING | CASCADE DEVELOPMENT, INC. A SUBSIDIARY OF CARDINAL HEALTH, INC. (US) | 1999-10-19 | — | — | US | claimed |
| US-5665802-A | REACTING POLYAMIC ACID WITH A DEHYDRATION-CYCLIZATION AGENT, A CATALYST AND AN ORGANIC PHOSPHORUS COMPOUND; EXCELLENT IN TENSILE STRENGTH AND FLEXIBILITY | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-09-09 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5543157-A | PHARMACEUTICAL INCLUSION COMPOUNDS PROVIDING FAST RELEASE OF DRUG WHEN WETTED WITH WATER, E.G. BODY FLUIDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-08-06 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |